These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 15026583

  • 1. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G, Strand V, Leflunomide Multinational Study Group.
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [Abstract] [Full Text] [Related]

  • 2. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V.
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [Abstract] [Full Text] [Related]

  • 3. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R, European Leflunomide Study Group.
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P, Treatment of Psoriatic Arthritis Study Group.
    Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
    Furst DE, Saag K, Fleischmann MR, Sherrer Y, Block JA, Schnitzer T, Rutstein J, Baldassare A, Kaine J, Calabrese L, Dietz F, Sack M, Senter RG, Wiesenhutter C, Schiff M, Stein CM, Satoi Y, Matsumoto A, Caldwell J, Harris RE, Moreland LW, Hurd E, Yocum D, Stamler DA.
    Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
    [Abstract] [Full Text] [Related]

  • 6. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G.
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A, Rodrigues J, Fiechtner J, Berger M, Pan S.
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [Abstract] [Full Text] [Related]

  • 8. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, Dorrier C, Thompson A.
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B, Breedveld F.
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [Abstract] [Full Text] [Related]

  • 10. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    Dougados M, Emery P, Lemmel EM, Zerbini CA, Brin S, van Riel P.
    Ann Rheum Dis; 2005 Jan; 64(1):44-51. PubMed ID: 15271770
    [Abstract] [Full Text] [Related]

  • 11. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms.
    Williams GW, Kivitz AJ, Brown MT, Verburg KM.
    Clin Ther; 2006 Feb; 28(2):204-21. PubMed ID: 16678642
    [Abstract] [Full Text] [Related]

  • 12. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C, Chen S, Gu Y, Lao Z, Ni L, Yu Q, Xu J, Li X, Liu J, Sun L, He P, Ma J, Xu S, Ding C.
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [Abstract] [Full Text] [Related]

  • 13. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI.
    Scand J Rheumatol; 2009 Aug; 38(1):11-4. PubMed ID: 19191187
    [Abstract] [Full Text] [Related]

  • 14. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE.
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [Abstract] [Full Text] [Related]

  • 15. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M.
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [Abstract] [Full Text] [Related]

  • 17. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tacrolimus (FK506) in treatment of rheumatoid arthritis: a randomized, double blind, placebo controlled dose-finding study.
    Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S.
    J Rheumatol; 2004 Feb; 31(2):243-51. PubMed ID: 14760792
    [Abstract] [Full Text] [Related]

  • 19. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study.
    Bruyn GA, Tate G, Caeiro F, Maldonado-Cocco J, Westhovens R, Tannenbaum H, Bell M, Forre O, Bjorneboe O, Tak PP, Abeywickrama KH, Bernhardt P, van Riel PL, RADD Study Group.
    Ann Rheum Dis; 2008 Aug; 67(8):1090-5. PubMed ID: 18037627
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.
    Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX.
    Chin Med J (Engl); 2008 Apr 05; 121(7):615-9. PubMed ID: 18466681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.